MaxiVAX wins 2017 CTI Swiss Medtech Award

The 2017 CTI Swiss Medtech Award, presented at the Swiss Medtech Day on 13 June, has gone to the biotech company MaxiVAX. MaxiVAX and the Geneva University Hospitals received the CHF 15,000 prize for developing a new vaccine designed to help the immune system in cancer patients fight their own tumor cells. The award was presented by Federal Councillor Johann N. Schneider-Ammann before around 600 guests in the Kursaal, Bern.

Press release in English, French, German, Italian

Download the poster.


Maxivax is 1 of 3 companies nominated to receive the CTI Swiss Medtech Award 2017. The winner announcement and Award ceremony will be held in Bern during the Swiss Medtech Day, on June 13th 2017.


Maxivax is presenting the final data of the primary endpoint of its First-In-Man study at the ESMO 2016 congress in Copenhagen.

See the poster.


MaxiVAX announces promising results from its phase 1 anti-cancer clinical trial

Read the full press release.


Press Release: MaxiVAX appoints Dimitrios Goundis as Chief Executive Officer

Read the full press release.


Poster Cell-based immunotherapy combining encapsulation cell technology and irradiated autologous tumor cells: A novel technology platform that is both safe and feasible. Results from MVX-ONCO-1 first-in-man Phase 1 Trial. 


MaxiVAX will participate in the Bio-Europe 2015 conference, Munich, Germany, Nov 2-4, 2015


MVX-ONCO-1: First in man, Phase I clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results" has been selected by the 18th ECCO - 40th ESMO European Cancer Congress Scientific Committee as a Poster in the poster session "Immunotherapy of Cancer" on 26 September 2015 from 16:45 to 18:45 in Hall C. The poster has also been selected for a new special session called Poster Spotlight from 17:15 to 18:15